CompletedPhase 2NCT01534637
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Wake Forest University Health Sciences
- Principal Investigator
- Arthur BlackstockWake Forest University Health Sciences
- Intervention
- aprepitant(drug)
- Enrollment
- 22 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2012
Study locations (1)
- Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Collaborators
National Cancer Institute (NCI) · Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01534637 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNANCT07263217Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver InjurySecond Affiliated Hospital, School of Medicine, Zhejiang University